{"id":60420,"date":"2024-02-28T06:48:16","date_gmt":"2024-02-28T06:48:16","guid":{"rendered":"https:\/\/medsname.com\/riscon\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"riscon","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/riscon\/","title":{"rendered":"Riscon"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Riscon?<\/h3>\n
\n

Riscon<\/strong> obsahuje risperidon<\/strong> od v\u00fdrobce s certifikac\u00ed WHO-GMP (Sun Pharma) \u2014 jeden z nej\u010dast\u011bji p\u0159edepisovan\u00fdch atypick\u00e1 antipsychotika<\/strong> celosv\u011btov\u011b. Schv\u00e1leno FDA pro l\u00e9\u010dbu schizofrenie (dosp\u011bl\u00ed a adolescenti 13+), bipol\u00e1rn\u00ed m\u00e1nie (dosp\u011bl\u00ed a v\u011bk 10+) a podr\u00e1\u017ed\u011bnosti u autismu (d\u011bti 5+). Mechanismus: siln\u00e1 D2<\/sub> + 5-HT2A<\/sub> antagonismus. Standardn\u00ed d\u00e1vka pro dosp\u011bl\u00e9: 2\u20136 mg\/den<\/strong> (za\u010dn\u011bte 0,5\u20131 mg, postupn\u011b titrujte). V\u00fdrazn\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky<\/strong>: nejvy\u0161\u0161\u00ed hyperprolaktin\u00e9mie<\/strong> u atypick\u00fdch antipsychotik (galaktorhea, gynekomastie, amenorea, sexu\u00e1ln\u00ed dysfunkce); EPS p\u0159i d\u00e1vk\u00e1ch > 6 mg\/den (atypick\u00e9 \u2192 typick\u00e9 \u201cp\u0159ek\u0159\u00ed\u017een\u00e9\u201d chov\u00e1n\u00ed); st\u0159edn\u00ed metabolick\u00e1 z\u00e1t\u011b\u017e. FDA \u010dern\u00e9 varov\u00e1n\u00ed pro mortalitu u star\u0161\u00edch pacient\u016f s demenc\u00ed<\/strong>.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<\/div>\n

D\u016fle\u017eit\u00e9 \u2014 nejedn\u00e1 se o l\u00e9k na situa\u010dn\u00ed \u00fazkost.<\/strong> Riscon je atypick\u00fdch antipsychotik<\/strong>, p\u0159edepisov\u00e1n a titrov\u00e1n po t\u00fddny pro schizofrenie, bipol\u00e1rn\u00ed m\u00e1nie a podr\u00e1\u017ed\u011bnost spojen\u00e1 s autismem u d\u011bt\u00ed<\/strong>. Nen\u00ed ne<\/strong> spr\u00e1vn\u00fdm l\u00e9kem pro akutn\u00ed, v\u00fdkonov\u011b souvisej\u00edc\u00ed \u00fazkost (l\u00e9t\u00e1n\u00ed, ve\u0159ejn\u00e9 vystupov\u00e1n\u00ed, zkou\u0161ky) \u2014 pro tyto p\u0159\u00edpady jsou klinicky vhodn\u011bj\u0161\u00ed betablok\u00e1tory (propranolol), benzodiazepiny nebo hydroxyzin. Pokud nem\u00e1te diagnostikovanou poruchu n\u00e1lady, \u00fazkostnou nebo psychiatrickou poruchu, neza\u010d\u00ednejte s u\u017e\u00edv\u00e1n\u00edm tohoto l\u00e9ku.<\/div>\n
FDA \u010dern\u00e9 varov\u00e1n\u00ed \u2014 mortalita u star\u0161\u00edch pacient\u016f s demenc\u00ed.<\/strong> V\u0161echna antipsychotika (atypick\u00e1 i konven\u010dn\u00ed) nesou FDA \u010dern\u00e9 varov\u00e1n\u00ed pro zv\u00fd\u0161enou mortalitu p\u0159i l\u00e9\u010db\u011b psych\u00f3zy nebo behavior\u00e1ln\u00edch poruch souvisej\u00edc\u00edch s demenc\u00ed u star\u0161\u00edch pacient\u016f. Tento l\u00e9k je FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> pro p\u0159\u00edznaky spojen\u00e9 s demenc\u00ed.<\/div>\n

Co je Riscon?<\/h2>\n

Riscon je peror\u00e1ln\u00ed tableta risperidon<\/strong> vyr\u00e1b\u011bn\u00e1 spole\u010dnost\u00ed Sun Pharma. Risperidon (americk\u00e1 zna\u010dka Risperdal<\/strong>) byl uveden na trh spole\u010dnost\u00ed Janssen v roce 1993 a pat\u0159\u00ed mezi nej\u010dast\u011bji p\u0159edepisovan\u00e9 atypick\u00e9 antipsychotika na sv\u011bt\u011b. Jedn\u00e1 se o siln\u00fd D2<\/sub> a 5-HT2A<\/sub> antagonista<\/strong> s dodate\u010dnou blok\u00e1dou alfa-1, alfa-2 a H1<\/sub> . Siln\u011bj\u0161\u00ed vazba na D2<\/sub> ve srovn\u00e1n\u00ed s jin\u00fdmi atypick\u00fdmi antipsychotiky znamen\u00e1, \u017ee se risperidon ve vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch chov\u00e1 sp\u00ed\u0161e jako antipsychotikum prvn\u00ed generace \u2014 s rizikem EPS nad 6 mg\/den. Aktivn\u00ed metabolit paliperidon (9-OH-risperidon) m\u00e1 v\u00fdznamn\u00fd pod\u00edl na klinick\u00e9m \u00fa\u010dinku a je samostatn\u011b uv\u00e1d\u011bn na trh jako Invega.<\/p>\n

Schv\u00e1len\u00e9 indikace<\/h2>\n
    \n
  • Schizofrenii<\/strong> \u2014 dosp\u011bl\u00ed a adolescenti (v\u011bk 13+)<\/li>\n
  • Bipol\u00e1rn\u00ed m\u00e1nie (akutn\u00ed)<\/strong> \u2014 dosp\u011bl\u00ed a d\u011bti (v\u011bk 10+); monoterapie nebo v kombinaci s lithiem \/ valpro\u00e1tem<\/li>\n
  • Podr\u00e1\u017ed\u011bnost spojen\u00e1 s autismem<\/strong> \u2014 d\u011bti (v\u011bk 5+); agrese, sebepo\u0161kozuj\u00edc\u00ed chov\u00e1n\u00ed, siln\u00e9 z\u00e1chvaty vzteku<\/li>\n
  • Mimo indikaci: behavior\u00e1ln\u00ed poruchy u demence (pou\u017e\u00edvat velmi opatrn\u011b \u2014 \u010dern\u00e9 varov\u00e1n\u00ed), Tourett\u016fv syndrom, l\u00e9\u010dba rezistentn\u00ed deprese, augmentace u OCD<\/li>\n<\/ul>\n

    D\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n\n\n
    Indikace<\/th>\nStart<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u011b<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    Schizofrenie (dosp\u011bl\u00ed)<\/td>\n1 mg 2x denn\u011b nebo 2 mg na noc<\/td>\n4\u20138 mg\/den<\/td>\n16 mg\/den<\/td>\nV\u011bt\u0161ina l\u00e9ka\u0159\u016f p\u0159edepisuje 2\u20136 mg\/den \u2014 riziko EPS prudce stoup\u00e1 nad 6 mg\/den<\/td>\n<\/tr>\n
    Schizofrenie (dosp\u00edvaj\u00edc\u00ed 13+)<\/td>\n0,5 mg HS<\/td>\n3 mg\/den<\/td>\n6 mg\/den<\/td>\nStandardn\u00ed c\u00edlov\u00e1 d\u00e1vka pro dosp\u00edvaj\u00edc\u00ed<\/td>\n<\/tr>\n
    Bipol\u00e1rn\u00ed m\u00e1nie (dosp\u011bl\u00ed)<\/td>\n2\u20133 mg HS<\/td>\n1\u20136 mg\/den<\/td>\n6 mg\/den<\/td>\nTypick\u00e9 jednodenn\u00ed pod\u00e1v\u00e1n\u00ed HS<\/td>\n<\/tr>\n
    Dr\u00e1\u017edivost p\u0159i autismu (5\u201316 let, < 20 kg)<\/td>\n0,25 mg\/den<\/td>\n0,5\u20133 mg\/den na z\u00e1klad\u011b hmotnosti<\/td>\n\u2014<\/td>\nPomal\u00e1 titrace; p\u0159ehodnotit po 4\u20136 t\u00fddnech<\/td>\n<\/tr>\n
    Star\u0161\u00ed pacienti<\/td>\n0,25\u20130,5 mg BID<\/td>\n1\u20132 mg\/den<\/td>\n\u2014<\/td>\nV\u00fdznamn\u00e9 riziko ortostatick\u00e9 hypotenze a p\u00e1d\u016f; varov\u00e1n\u00ed p\u0159ed demenc\u00ed v \u010dern\u00e9m r\u00e1me\u010dku<\/td>\n<\/tr>\n
    Jatern\u00ed\/ren\u00e1ln\u00ed selh\u00e1n\u00ed<\/td>\n0,5 mg dvakr\u00e1t denn\u011b<\/td>\nPomalej\u0161\u00ed titrace<\/td>\n\u2014<\/td>\nPolovi\u010dn\u00ed obvykl\u00e9 d\u00e1vkovac\u00ed p\u0159\u00edr\u016fstky<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n

    Profil ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Frekvence<\/th>\n\u00da\u010dinek<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    B\u011b\u017en\u00e9<\/td>\nHyperprolaktin\u00e9mie<\/td>\nNejvy\u0161\u0161\u00ed mezi atypick\u00fdmi antipsychotiky \u2013 galaktorea, gynekomastie, amenorea, sexu\u00e1ln\u00ed dysfunkce; p\u0159i p\u0159\u00edznac\u00edch kontrolovat prolaktin<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nSedace, \u00fanava<\/td>\nSt\u0159edn\u00ed; m\u00e9n\u011b ne\u017e kvetiapin<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nP\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze<\/td>\nSt\u0159edn\u00ed (3\u20135 kg za 12 m\u011bs\u00edc\u016f)<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nOrtostatick\u00e1 hypotenze<\/td>\nBlok\u00e1da alfa-1<\/td>\n<\/tr>\n
    \u010cast\u00e9 (z\u00e1visl\u00e9 na d\u00e1vce)<\/td>\nExtrapyramidov\u00e9 p\u0159\u00edznaky (akathisie, parkinsonismus, dystonie)<\/td>\nVy\u0161\u0161\u00ed ne\u017e u jin\u00fdch atypick\u00fdch antipsychotik; v\u00fdznamn\u00e9 nad 6 mg\/den<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nAnticholinergn\u00ed \u00fa\u010dinky (sucho v \u00fastech, z\u00e1cpa)<\/td>\nM\u00edrn\u00fd<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nMetabolick\u00fd syndrom (gluk\u00f3za, lipidy)<\/td>\nSt\u0159edn\u00ed \u2014 m\u00e9n\u011b ne\u017e olanzapin \/ kvetiapin; z\u00e1kladn\u00ed hodnoty + monitorov\u00e1n\u00ed<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nTardivn\u00ed dyskineze<\/td>\nNi\u017e\u0161\u00ed ne\u017e u antipsychotik prvn\u00ed generace; riziko roste s d\u00e9lkou u\u017e\u00edv\u00e1n\u00ed<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nProdlou\u017een\u00ed QT intervalu<\/td>\nM\u00edrn\u00e9 \u2014 m\u00e9n\u011b ne\u017e ziprasidon<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nNeuroleptick\u00fd malign\u00ed syndrom<\/td>\nNouzov\u00fd stav<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nC\u00e9vn\u00ed mozkov\u00e1 p\u0159\u00edhoda \/ TIA u star\u0161\u00edch pacient\u016f<\/td>\nVarov\u00e1n\u00ed \u010dern\u00e9ho r\u00e1me\u010dku pro demenci<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Interakce s l\u00e9\u010divy<\/h2>\n

    Substr\u00e1t CYP2D6<\/strong>: hladiny stoupaj\u00ed p\u0159i u\u017e\u00edv\u00e1n\u00ed siln\u00fdch inhibitor\u016f (paroxetin, fluoxetin, bupropion, chinidin) \u2014 sni\u017ete d\u00e1vku. Induktory CYP3A4 (karbamazepin, rifampicin, fenytoin) sni\u017euj\u00ed hladiny \u2014 je t\u0159eba vy\u0161\u0161\u00ed d\u00e1vka.<\/p>\n

    Aditivn\u00ed sedace \/ ortostatick\u00e1 hypotenze<\/strong>: alkohol, benzodiazepiny, opioidy, antihypertenziva.<\/p>\n

    Prodlou\u017een\u00ed QT intervalu<\/strong>: opatrnost p\u0159i u\u017e\u00edv\u00e1n\u00ed citalopramu (vysok\u00e9 d\u00e1vky), ondansetronu, metadonu.<\/p>\n

    Anti-Parkinsonova l\u00e9\u010diva<\/strong>: antagonismus \u2014 risperidon D2<\/sub> blok\u00e1da sni\u017euje dopaminergn\u00ed \u00fa\u010dinek levodopy, ropinirolu, pramipexolu.<\/p>\n

    Hyperprolaktin\u00e9mie \u2014 probl\u00e9m s risperidonem<\/h2>\n

    Risperidon je nejv\u00edce prolaktin zvy\u0161uj\u00edc\u00ed atypick\u00fd antipsychotikum<\/strong>. Mechanismus je tuberoinfundibul\u00e1rn\u00ed D2<\/sub> blok\u00e1da v hypof\u00fdze, kter\u00e1 odstran\u00ed norm\u00e1ln\u00ed dopaminovou inhibici uvol\u0148ov\u00e1n\u00ed prolaktinu. Klinick\u00e9 d\u016fsledky:<\/p>\n